Immunglobulin M Enriched Intra Venous Immunoglobulin (IVIG) Therapy in Adult Respiratory Distress Syndrom (ARDS) Patients
NCT ID: NCT02961166
Last Updated: 2018-04-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
57 participants
OBSERVATIONAL
2012-01-31
2016-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
These patients were analyzed regarding length of stay in intensive care unit (LOS ICU), length of stay (LOS) in hospital and regarding mortality.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Non-invasive Fluid Management
NCT02892799
Infusion Rate and Volume Kinetics for Hyperoncotic Albumine in Healthy Subjects
NCT03453320
Effects of Induced Moderate Hypothermia on ARDS Patients Under Venovenous ExtraCorporeal Membrane Oxygenation
NCT05306392
Post-Operative Use of Salt Poor Albumin Solution in Resuscitation of Orthotopic Liver Transplant
NCT00842803
The Effect of Restrictive Fluid Management on Cardiac Function and Glycocalyx Degradation
NCT04282252
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Patient characteristics, like Acute Physiology And Chronic Health Evaluation (APACHE) and Sepsis-related organ failure assessment (SAPS) Score, preexisting diseases, origin of infection, duration of ECMO therapy were analyzed in these patients.
These patients were further analyzed regarding LOS ICU, LOS in hospital and regarding mortality.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
IgM enriched Immunoglobulins
ARDS patients with septic shock requiring ECMO therapy were treated for 3 days by IgM-enriched Immunoglobulin
IgM enriched Immunoglobulins
Treatment for 3 days
Control
ARDS patients with septic shock requiring ECMO therapy were NOT treated by IgM-enriched Immunoglobulin
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
IgM enriched Immunoglobulins
Treatment for 3 days
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* ARDS with ECMO therapy
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Universität Tübingen
OTHER
University Hospital Tuebingen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
PD Dr. Helene Haeberle
PD Dr. med. Helene Haeberle
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Helene A Haeberle, MD
Role: PRINCIPAL_INVESTIGATOR
University Hospital Tuebingen
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital Tuebingen
Tübingen, , Germany
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Prohaska S, Schirner A, Bashota A, Korner A, Blumenstock G, Haeberle HA. Intravenous immunoglobulin fails to improve ARDS in patients undergoing ECMO therapy. J Intensive Care. 2018 Feb 26;6:11. doi: 10.1186/s40560-018-0278-8. eCollection 2018.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
University Hospital Tuebingen
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.